UBS O'Connor’s Arcus Biosciences RCUS Stock Holding History

UBS O'Connor’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-38,000	Closed	-$171K	–	703
2022 Q4	$171K	Buy	+38,000	New	+$1.05M	﹤0.01%	652

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS O'Connor's RCUS Position: Q3 2025 in Review

UBS O'Connor sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 52,975 shares — an estimated $431K sold.

UBS O'Connor first reported a position in RCUS in Q2 2022 and held it in 13 quarters. The position peaked at $2.12M in Q2 2023. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

UBS O'Connor reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 52,975 Arcus Biosciences shares in Q3 2025, an estimated $431K.
UBS O'Connor first reported a position in Arcus Biosciences in Q2 2022 and held it in 13 quarters.
UBS O'Connor's Arcus Biosciences position peaked at $2.12M in Q2 2023.
190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.